06:58:45 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-02-02 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning CRAD B 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-01-26 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning CRAD B 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-29 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning CRAD B 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-31 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning CRAD B 0.00 SEK
2020-05-08 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-01-31 Bokslutskommuniké 2019
2019-12-17 Extra Bolagsstämma 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CRAD B 0.00 SEK
2019-05-08 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-05-31 Årsstämma 2018
2018-05-18 Ordinarie utdelning CRAD B 0.00 SEK
2018-04-26 Kvartalsrapport 2018-Q1
2018-01-31 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-02 Ordinarie utdelning CRAD B 0.00 SEK
2017-04-28 Årsstämma 2017
2017-04-28 Kvartalsrapport 2017-Q1
2017-02-13 Bokslutskommuniké 2016
2016-11-17 Extra Bolagsstämma 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-09 Kvartalsrapport 2016-Q1
2016-04-15 Ordinarie utdelning CRAD B 0.00 SEK
2016-04-14 Årsstämma 2016
2016-02-08 Bokslutskommuniké 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-08 Kvartalsrapport 2015-Q1
2015-04-17 Ordinarie utdelning CRAD B 0.00 SEK
2015-04-16 Årsstämma 2015
2015-01-30 Bokslutskommuniké 2014
2014-11-07 Analytiker möte 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-15 Kvartalsrapport 2014-Q2
2014-05-16 Kvartalsrapport 2014-Q1
2014-04-17 Ordinarie utdelning CRAD B 0.00 SEK
2014-04-16 Årsstämma 2014
2014-02-17 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-11-01 Analytiker möte 2013
2013-10-30 Extra Bolagsstämma 2013
2013-09-02 15-7 2013
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-03 Ordinarie utdelning CRAD B 0.00 SEK
2013-05-31 Årsstämma 2013
2013-05-29 Kvartalsrapport 2013-Q1
2013-02-26 Bokslutskommuniké 2012
2012-12-04 Extra Bolagsstämma 2012
2012-11-28 Kvartalsrapport 2012-Q3
2012-09-04 Kvartalsrapport 2012-Q2
2012-06-04 Ordinarie utdelning CRAD B 0.00 SEK
2012-06-01 Årsstämma 2012
2012-05-24 Kvartalsrapport 2012-Q1
2012-02-24 Bokslutskommuniké 2011
2011-11-25 Kvartalsrapport 2011-Q3
2011-08-26 Kvartalsrapport 2011-Q2
2011-05-26 Ordinarie utdelning CRAD B 0.00 SEK
2011-05-25 Årsstämma 2011
2011-05-24 Kvartalsrapport 2011-Q1
2011-02-11 Bokslutskommuniké 2010
2010-06-02 Ordinarie utdelning CRAD B 0.00 SEK
2010-06-01 Årsstämma 2010
2010-05-28 Kvartalsrapport 2010-Q1
2009-11-27 Kvartalsrapport 2009-Q3


ListaSmall Cap Stockholm
C-Rad är verksamma inom medicinteknik. Bolaget bedriver utveckling, tillverkning och försäljning av produkter och lösningar inom avancerad strålterapi. Verksamheten riktar sig huvudsakligen mot kliniker som erbjuder strålbehandling, där bolaget utöver kärnverksamheten erbjuder tillhörande installationstjänster och support. Kunderna återfinns på global nivå och huvudkontoret ligger i Uppsala.
2021-12-17 09:30:00

C-RAD is pleased to announce that Catalyst+ HD™ has been successfully validated at the MVZ Prof. Dr. Uhlenbrock & Partner, Medical Centre in Dortmund, Germany for use with their new Elekta Harmony linear accelerators. Elekta and C-RAD continue to work together driving the development of Surface Guided Radiation Therapy (SGRT) as the standard of care in Radiotherapy.

The installation in Dortmund is yet another milestone in this endeavor and the site is now one of the only hospitals in the world with this combined state-of-the art technology, enabling the clinic to offer their patients the best care available today.

All Elekta linear accelerators (linacs) are now certified for compatibility with the full capabilities of the Catalyst family of products. Including patient positioning, real time motion monitoring and respiratory gated treatment, automated couch adjustments using the Elekta’s MOSAIQ® interface, and automatic beam control using the Response™ interface, presenting all global customers with the opportunity to offer the same highly modern set-up for their treatment rooms.

“At MVZ Prof. Dr. Uhlenbrock and Partner we pride ourselves in always being in the forefront of the latest techniques and offering our patients the best available treatment in the field. The set-up with Elekta’s Harmony and C-RAD’s Sentinel™ and Catalyst+ HD™ will allow us to increase our treatment efficiency as well as our patient safety, something that lies at the heart of our strong focus for state-of-the-art patient service.” says Prof. Dr. Detlev Uhlenbrock (Managing Director of MVZ Prof. Dr. Uhlenbrock und Partner).
Catalyst+ HD has been validated for interoperability with the Elekta Versa HD™, Infinity™ and Synergy ® linear accelerators, and we are pleased to announce that the Catalyst is the first SGRT system available and validated for use with the Elekta Harmony.
A cancer treatment system designed to meet healthcare centres’ need for a productive, precise, and versatile radiotherapy treatment system, Elekta Harmony perfectly balances productivity, versatility, and precision without compromise, making it a solution for both mature and developing markets.
“Harmony is designed to allow centres to increase patient throughput without compromising on precision or versatility to treat a wide patient population. Validating Catalyst+ HD with Harmony is a next step in ensuring we provide the clinical versatility our customers expect while recognising the growing demand for Surface Image Guidance in radiation therapy,” says Elekta’s Marie Macary, Vice President and Head of Marketing and Sales, Linac Solutions.
“We are delighted to showcase the integration and demonstrate the benefits of combining Catalyst+ HD and Harmony. Once more C-RAD is pioneering and we are proud that Catalyst+ HD can be offered to all Elekta Linac customers, which is part of our goal to establish SGRT as the standard of care.” says Tim Thurn, CEO and President at C-RAD AB, “Interoperability and connectivity are crucial for efficient and safe patient treatments, and we are excited to see the Catalyst+ HD contribution to Elekta Harmony treatments success.”

About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient’s motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD. Inspiring excellence in cancer treatment.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
About MVZ Prof. Dr. Uhlenbrock und Partner
MVZ Prof Dr. Uhlenbrock und Partner is one of the leading centers for radiology, radiotherapy and nuclear medicine in the Ruhr area and in Westphalia. At 17 locations in clinics and medical centers, it is offered imaging diagnostics, pain treatments and radiation therapies according to the latest standards. In addition to modern equipment of our practices with high-tech medical equipment, this group is focused on a modern and patient-oriented service.
For further information about Prof. Dr. Uhlenbrock und Partner:
Tim Wallentin, Christopher Badde (U&P Service GmbH)
Tel: +49 231 9433-6, e-mail: redaktion@mvz-uhlenbrock
Time zone: CET: Central European Time